Document is current
Any future updates will be listed below
-
Authors
Appel, Katharina S.
Lee, Chin Huang
Nunes de Miranda, Susana M.
Maier, Daniel
Reese, Jens-Peter
Anton, Gabriele
Bahmer, Thomas
Ballhausen, Sabrina
Balzuweit, Beate
Bellinghausen, Carla
Blumentritt, Arne
Brechtel, Markus
Chaplinskaya-Sobol, Irina
Erber, Johanna
Fiedler, Karin
Geisler, Ramsia
Heyder, Ralf
Illig, Thomas
Kohls, Mirjam
Kollek, Jenny
Krist, Lilian
Lorbeer, Roberto
Miljukov, Olga
Mitrov, Lazar
Nürnberger, Carolin
Pape, Christian
Pley, Christina
Schäfer, Christian
Schaller, Jens
Schattschneider, Mario
Scherer, Margarete
Schulze, Nick
Stahl, Dana
Stubbe, Hans Christian
Tamminga, Thalea
Tebbe, Johannes Josef
Vehreschild, Maria J. G. T.
Wiedmann, Silke
Vehreschild, Jörg Janne
-
Funding
Funding for this research was provided by:
German Federal Ministry of Education and Research (01KX2021, 01KX2121)
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 3 June 2024
First Online: 13 June 2024
Competing interests
: DM received speaker honoraria from Free University of Berlin and travel compensation from IQVIA. JPR received consulting fees and personal fees (written expertise on data linkage) from the German Ministry for Heath. JPR has grants from the German Ministry of Research and Education (BMBF): Network University Medicine (NUM), CArdiovascular diseases – Enhancing Healthcare through cross-sectoral Routine data integration (CAEHR), Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis (ACRIBIS), EVAluation research based on data from routine clinical care 4 the MII (EVAL4MII); Bavarian State (Ministry for Science and the Arts): Digital Oncology (DigiOnko); Federal Joint Committee (GBA) within the Innovationsfonds: Perioperative interdisciplinary, intersectoral process optimization (Peri-OP), Patient typology for needs-based and more effective coaching in patients with hormone receptor-positive breast cancer (Pa-Typ). JJV has personal fees from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universitätsmedizin (NUM), Janssen, NordForsk, Biontech, APOGEPHA. JJV has grants from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zetrum für Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen, Network University Medicine. All other authors declare that they have no competing interests.
